Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity
Eur J Prev Cardiol. 2026 Aug 10:zwag408. doi: 10.1093/eurjpc/zwag408. Online ahead of print.ABSTRACTAIM: This post hoc analysis assessed the durability of tirzepatide for primary cardiovascular disease (CVD) prevention in obesity, based on predicted CVD risk, in the SURMOUNT-1 (SM-1) 3-year study.ME

